No price history available.
Key financial summary
Financials in JPY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | 2027E | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | ¥m | 412,826 | 393,568 | 467,937 | 538,026 | 558,056 | 586,531 | 579,629 | N/A | N/A |
| Operating profit | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | ¥m | 4,978 | 19,713 | 31,254 | 40,683 | 55,835 | 49,481 | 10,181 | N/A | N/A |
| EPS reported | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in JPY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | 2027E | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Value | ||||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | ||||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | ||||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | ||||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Daicel Corporation, a Japanese enterprise founded in Osaka in 1919, conducts its business operations across Japan, Asia, North America, and Europe. The company is a key producer and distributor of a broad array of products, including cellulosic derivatives, organic chemicals, diverse plastics, and pyrotechnic devices. Its extensive activities are organized into distinct segments: Medical/Healthcare, Smart, Safety, Materials, Engineering Plastics, and other specialized areas. In the Medical/Healthcare sector, Daicel supplies various cosmetic components such as 1,3-Butylene glycol, polyglycerin, and thickeners, in addition to natural health food ingredients and dietary supplements. For the pharmaceutical industry, it provides specialized chiral and achiral columns, a variety of chiral and bio reagents, and DNA/RNA-based probes, supported by comprehensive analytical, purification, synthesis, formulation, and specialized analytical tool services. The "Smart" segment focuses on advanced materials for the electronics industry, offering triacetylcellulose and films for display technologies, solvents for electronic applications, polymers for resist processes, and cleaning agents for semiconductors. Moreover, Daicel contributes to visualization technologies with its optical components, lens units, silver nanoparticle inks, and organic semiconductor devices. Within the Safety domain, the company manufactures inflators for vehicle airbags and pyro-fuses, alongside safety mechanisms for non-automotive products. Daicel is also a significant supplier of foundational chemicals and raw materials, including acetic acid and its derivatives, cellulose acetate, and acetate tow for resins, inks, and paint solvents. It further develops specialty chemicals such as cycloaliphatic epoxies, caprolactone, ketene derivatives, and alkylamines, which are vital for electrical materials and coatings. For the Engineering Plastics segment, Daicel delivers a wide selection of plastic solutions, encompassing engineering plastics, plastic compound products, functional sheets, molded trays, and packaging films. Beyond these core offerings, the company also produces water treatment systems and diffusers tailored for diverse industrial requirements. Daicel's comprehensive portfolio plays a crucial role in various sectors, including transportation, electronics, medical care, personal care, daily life, and environmental and energy applications. The company, which was initially named Daicel Chemical Industries, Ltd., officially adopted its current name, Daicel Corporation, in October 2011.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Daicel Corporation (4202.T)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Daicel Corporation, a Japanese enterprise founded in Osaka in 1919, conducts its business operations across Japan, Asia, North America, and Europe. The company is a key producer and distributor of a broad array of products, including cellulosic derivatives, organic chemicals, diverse plastics, and pyrotechnic devices. Its extensive activities are organized into distinct segments: Medical/Healthcare, Smart, Safety, Materials, Engineering Plastics, and other specialized areas. In the Medical/Healthcare sector, Daicel supplies various cosmetic components such as 1,3-Butylene glycol, polyglycerin, and thickeners, in addition to natural health food ingredients and dietary supplements. For the pharmaceutical industry, it provides specialized chiral and achiral columns, a variety of chiral and bio reagents, and DNA/RNA-based probes, supported by comprehensive analytical, purification, synthesis, formulation, and specialized analytical tool services. The "Smart" segment focuses on advanced materials for the electronics industry, offering triacetylcellulose and films for display technologies, solvents for electronic applications, polymers for resist processes, and cleaning agents for semiconductors. Moreover, Daicel contributes to visualization technologies with its optical components, lens units, silver nanoparticle inks, and organic semiconductor devices. Within the Safety domain, the company manufactures inflators for vehicle airbags and pyro-fuses, alongside safety mechanisms for non-automotive products. Daicel is also a significant supplier of foundational chemicals and raw materials, including acetic acid and its derivatives, cellulose acetate, and acetate tow for resins, inks, and paint solvents. It further develops specialty chemicals such as cycloaliphatic epoxies, caprolactone, ketene derivatives, and alkylamines, which are vital for electrical materials and coatings. For the Engineering Plastics segment, Daicel delivers a wide selection of plastic solutions, encompassing engineering plastics, plastic compound products, functional sheets, molded trays, and packaging films. Beyond these core offerings, the company also produces water treatment systems and diffusers tailored for diverse industrial requirements. Daicel's comprehensive portfolio plays a crucial role in various sectors, including transportation, electronics, medical care, personal care, daily life, and environmental and energy applications. The company, which was initially named Daicel Chemical Industries, Ltd., officially adopted its current name, Daicel Corporation, in October 2011.
